Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• BCL-2-associated athanogene-1L (BAG-1L) is a co-regulator of androgen receptor signaling, implicated in prostate cancer progression.
• Existing research on BAG-1L protein expression in advanced prostate cancer is limited by the lack of specific antibodies for the long isoform.

Purpose of the Study:

• To develop and validate a novel antibody specific for BAG-1L protein.
• To investigate BAG-1L protein expression in various human tissues, including normal, castration-sensitive prostate cancer (CSPC), and castration-resistant prostate cancer (CRPC).

Main Methods:

• Development and orthogonal validation of a BAG-1L-specific antibody.
• Immunohistochemistry on normal, CSPC, CRPC (primary and metastatic), and breast cancer tissues.
• Analysis of BAG-1L expression in matched CSPC and CRPC biopsies from the same patients.

Main Results:

• Higher BAG-1L protein expression was observed in CRPC metastases compared to early-stage prostate cancer in patients who remained recurrence-free.
• BAG-1L protein expression levels remained consistent between matched CSPC and CRPC biopsies from the same individuals.
• No significant association was found between BAG-1L protein expression and time to CRPC, overall survival, or response to therapies in CRPC patients.

Conclusions:

• The developed BAG-1L antibody is a valuable tool for further research into BAG-1L's role in cancer.
• BAG-1L protein expression may be linked to aggressive biology and castration resistance development in prostate cancer.
• BAG-1L expression levels do not appear to predict clinical outcomes or treatment response in advanced prostate cancer.